This Article Full Text Full Text (PDF) Correction (v16,p2797) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vineis, P. Articles by Perera, F. Search for Related Content PubMed PubMed Citation Articles by Vineis, P. Articles by Perera, F. Related Collections Epidemiology and Prevention Epidemiology and Prevention: Genetics and Biomarkers Commentary

Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old

¹ Department of Epidemiology and Public Health, Imperial College London, London, United Kingdom; ² Institute for Scientific Interchange Foundation, Torino, Italy; and ³ Department of Environmental Sciences and Columbia Center for Children's Environmental Health, Mailman School of Public Health, Columbia University, New York, New York

Requests for reprints: Frederica P. Perera, Department of Environmental Sciences and Columbia Center for Children's Environmental Health, Mailman School of Public Health, Columbia University, 100 Haven Avenue, Tower 3, #25F, New York, NY 10032. Phone: 212-304-7280; Fax: 212-544-1943. E-mail: fpp1{at}columbia.edu

The purpose of this review is to evaluate progress in molecular epidemiology over the past 24 years in cancer etiology and prevention to draw lessons for future research incorporating the new generation of biomarkers. Molecular epidemiology was introduced in the study of cancer in the early 1980s, with the expectation that it would help overcome some major limitations of epidemiology and facilitate cancer prevention. The expectation was that biomarkers would improve exposure assessment, document early changes preceding disease, and identify subgroups in the population with greater susceptibility to cancer, thereby increasing the ability of epidemiologic studies to identify causes and elucidate mechanisms in carcinogenesis. The first generation of biomarkers has indeed contributed to our understanding of risk and susceptibility related largely to genotoxic carcinogens. Consequently, interventions and policy changes have been mounted to reduce risk from several important environmental carcinogens. Several new and promising biomarkers are now becoming available for epidemiologic studies, thanks to the development of high-throughput technologies and theoretical advances in biology. These include toxicogenomics, alterations in gene methylation and gene expression, proteomics, and metabonomics, which allow large-scale studies, including discovery-oriented as well as hypothesis-testing investigations. However, most of these newer biomarkers have not been adequately validated, and their role in the causal paradigm is not clear. There is a need for their systematic validation using principles and criteria established over the past several decades in molecular cancer epidemiology. (Cancer Epidemiol Biomarkers Prev 2007;16(10):1954–65)

Commentary

Biomarkers for Cancer Risk, Early Detection, and Prognosis: The Validation Conundrum

Dean E. Brenner and Daniel P. Normolle
Cancer Epidemiol. Biomarkers Prev. 2007 16: 1918-1920. [Full Text] [PDF]

This article has been cited by other articles:

				Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2797 - 2797. [Full Text] [PDF]